Compare Duolingo Inc (DUOL) vs TransMedics Group Inc (TMDX) Price & Performance

Duolingo (DUOL) trades at $134.63, down 1.87% amid mixed signals. The stock shows strong fundamentals with impressive revenue growth from $369M in 2022 to $1.04B in 2025 and net income turning positive to $414M. Technical indicators show a bullish moving average trend but neutral oscillators, with key support at $134 and resistance at $138. Recent Q2 2026 earnings beat expectations with $0.66 EPS versus $0.604 expected, though Q3 revenue guidance disappointed investors.

The outlook remains cautiously optimistic with robust user growth and profitability metrics, but near-term pressure exists from decelerating booking growth and margin concerns. Analyst consensus is mixed with 30% buy ratings and a $121 price target below current levels. Key risks include monetization challenges despite user growth and increased competitive pressures in the education technology sector.

TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.

The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.